HC Wainwright Has Negative Outlook for NTLA FY2026 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at HC Wainwright decreased their FY2026 EPS estimates for Intellia Therapeutics in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($3.24) per share for the year, down from their previous estimate of ($3.06). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q1 2027 earnings at ($0.82) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.78) EPS and FY2027 earnings at ($3.17) EPS.

NTLA has been the subject of several other research reports. Wedbush raised their price objective on Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Thursday, October 15th. Citizens Jmp reiterated a “market outperform” rating and set a $30.00 target price on shares of Intellia Therapeutics in a report on Wednesday, September 9th. Barclays started coverage on Intellia Therapeutics in a research report on Tuesday, October 6th. They set an “underweight” rating and a $8.00 price target for the company. Finally, Wolfe Research downgraded Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price target for the company. in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have given a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $21.44.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $12.11 on Tuesday. The company’s 50-day moving average price is $12.08 and its two-hundred day moving average price is $13.04. Intellia Therapeutics has a one year low of $7.95 and a one year high of $18.48.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 5th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The business had revenue of $7.16 million during the quarter, compared to the consensus estimate of $9.74 million. During the same period last year, the business posted ($0.92) EPS. The firm’s revenue for the quarter was down 47.8% on a year-over-year basis.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 9,000 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $11.99, for a total value of $107,910.00. Following the completion of the sale, the chief executive officer owned 1,138,064 shares in the company, valued at $13,645,387.36. This trade represents a 0.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NTLA. Nykredit A S bought a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $33,000. Freestone Grove Partners LP acquired a new stake in Intellia Therapeutics in the 2nd quarter valued at about $33,000. Integrated Wealth Concepts LLC acquired a new stake in Intellia Therapeutics in the 2nd quarter valued at about $34,000. Farther Finance Advisors LLC lifted its stake in Intellia Therapeutics by 289.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,144 shares of the company’s stock valued at $26,000 after purchasing an additional 1,594 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in Intellia Therapeutics by 267.0% during the third quarter. Parallel Advisors LLC now owns 2,268 shares of the company’s stock worth $27,000 after purchasing an additional 1,650 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA.

Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.